Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04822363 · ClinicalTrials.gov registry record · Early Phase 1
The Accuracy Of A Novel Platelet Activity Assay In Humans On Antiplatelet Agents: Pharmacodynamics And Comparison With Light Transmission Aggregometry
A Early Phase 1 study, sponsored by Beth Israel Deaconess Medical Center.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 112
- Enrollment target
NCT04822363: Completed Early Phase 1 study, sponsored by Beth Israel Deaconess Medical Center.
NCT04822363 is a Early Phase 1 study that has completed, run by Beth Israel Deaconess Medical Center. The registered enrollment target is 112 participants, above the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (111% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04822363, a Early Phase 1 study, has completed, sponsored by Beth Israel Deaconess Medical Center.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 112 participants
- Enrollment target
Study Summary
The purpose of this study is to test a novel diagnostic immunoassay of platelet function and compare it to the current gold standard platelet function assay by testing the response to aspirin and clopidogrel in a group of healthy volunteers and severely obese individuals and comparing the accuracy of the two tests. The secondary goals will be to evaluate the pharmacodynamic parameters of the antiplatelet agents across the two testing modalities and refine the cutoffs used for the novel assay.
Primary Outcome
Sensitivity of pDrp1 assay for platelet inhibition at day 5
Interventions
- DRUG Aspirin
- DRUG Clopidogrel
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 112 participants |
| Start Date | 2021-08-20 |
| Est. Completion | 2025-06-30 |
| Phase | Early Phase 1 |
What the finished NCT04822363 record still lists
NCT04822363 is an interventional study that assigns participants to a tested intervention. The registered 112 participants enrollment target is mid-sized for trials with a published cap, above the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (111% higher).
The record links to 0 conditions, and to 2 interventions - of which Aspirin is the first listed.
NCT04822363 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04822363 about?
NCT04822363 is a clinical study titled "The Accuracy Of A Novel Platelet Activity Assay In Humans On Antiplatelet Agents: Pharmacodynamics And Comparison With Light Transmission Aggregometry". The purpose of this study is to test a novel diagnostic immunoassay of platelet function and compare it to the current gold standard platelet function assay by testing the response to aspirin and clopidogrel in a group of healthy volunteers and severely obese individuals and comparing the accuracy o...
What is the current status of trial NCT04822363?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 112 participants. The study started on 2021-08-20. Estimated completion is 2025-06-30.
What interventions are being tested in trial NCT04822363?
The interventions under investigation include: Aspirin (DRUG), Clopidogrel (DRUG).
Who is sponsoring clinical trial NCT04822363?
This trial is sponsored by Beth Israel Deaconess Medical Center, which has 488 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04822363's enrollment target sits among peer trials
112 165th of 2000 higher than 1,835 of 2,000 other Early Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Early Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04511013 · 112 participants · Phase 2
A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain Metastases
- NCT04551560 · 112 participants · NA
Stress and Congestive Heart Failure
- NCT04872166 · 112 participants · Phase 1
A Study of BTX-A51 in People With Advanced Solid Tumor and Breast Cancer
- NCT05024773 · 112 participants · Phase 3
Study of ONCOFID-P-B (PACLITAXEL-HYALURONIC ACID)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI